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ascular endothelial growth factor (VEGF) promotes
vascular permeability (VP) and neovascularization,
and is required for development. We ﬁnd that
VEGF-stimulated Src activity in chick embryo blood vessels
induces the coupling of focal adhesion kinase (FAK) to
integrin 
 
 
 
v
 
 
 
5, a critical event in VEGF-mediated signaling
and biological responsiveness. In contrast, FAK is constitutively
associated with 
 
 
 
1 and 
 
 
 
3 integrins in the presence or
absence of growth factors. In cultured endothelial cells,
VEGF, but not basic ﬁbroblast growth factor, promotes the
Src-mediated phosphorylation of FAK on tyrosine 861,
which contributes to the formation of a FAK/
 
 
 
v
 
 
 
5 signaling
V
 
complex. Moreover, formation of this FAK/
 
 
 
v
 
 
 
5 complex is
signiﬁcantly reduced in pp60
 
c-src
 
-deﬁcient mice. Supporting
these results, mice deﬁcient in either pp60
 
c-src
 
 or integrin
 
 
 
5, but not integrin 
 
 
 
3, have a reduced VP response to
VEGF. This FAK/
 
 
 
v
 
 
 
5 complex was also detected in epidermal
growth factor-stimulated epithelial cells, suggesting a
function for this complex outside the endothelium. Our
ﬁndings indicate that Src can coordinate speciﬁc growth
factor and extracellular matrix inputs by recruiting integrin
 
 
 
v
 
 
 
5 into a FAK-containing signaling complex during
growth factor–mediated biological responses.
 
Introduction
 
Vascular endothelial growth factor (
 
VEGF)* was originally
described as a vascular permeability (VP) factor secreted by
tumor cells, expressed in hypoxic tissues (Senger et al., 1983;
Connolly et al., 1989; Marti et al., 2000), mitogenic for en-
dothelial cells (Ferrara and Davis-Smyth, 1997), and essen-
tial for development (Carmeliet et al., 1996; Ferrara et al.,
1996). Recent evidence demonstrates that mice lacking the
nonreceptor tyrosine kinase, pp60
 
c-src
 
, have defects in
VEGF-mediated vascular responses (Eliceiri et al., 1999;
Paul et al., 2001). Specifically, in pp60
 
c-src
 
- or pp62
 
c-yes
 
-defi-
cient mice, the VP-promoting functions of VEGF were dis-
tinguished from the mitogenic functions of VEGF because
their blood vessels were resistant to VEGF-mediated VP,
even though these animals showed normal VEGF-mediated
angiogenesis (Eliceiri et al., 1999). However, chick embryos
or mice transduced with kinase-deleted Src, which sup-
presses multiple Src family kinases (SFKs), fail to undergo
VEGF-mediated angiogenesis (Eliceiri et al., 1999). To-
gether these findings demonstrate that, in general, SFKs are
compensatory during embryogenesis and angiogenesis, but
that VEGF-induced VP is dependent on a subset of SFKs,
such as Src or Yes (Eliceiri et al., 1999).
Angiogenesis requires the coordination of growth factor
receptors and integrins (Brooks et al., 1994; Friedlander et
al., 1995), leading to the activation of downstream signals in
endothelial cells (Eliceiri et al., 1998; Short et al., 1998).
Two pathways of growth factor–induced angiogenesis have
been identified in which basic FGF (bFGF) induces angio-
genesis dependent on integrin 
 
 
 
v
 
 
 
3 ligation, whereas VEGF
induces angiogenesis dependent on the ligation of integrin
 
 
 
v
 
 
 
5 (Friedlander et al., 1995). The mechanisms underly-
ing the selective coordination of inputs from growth factors
and the extracellular matrix (Plopper et al., 1995; Miyamoto
et al., 1996; Giancotti and Ruoslahti, 1999), such as the
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VEGF pathway with integrin 
 
 
 
v
 
 
 
5, remains poorly under-
stood. For example, whereas 
 
 
 
v
 
 
 
5-deficient mice develop
normally (Huang et al., 2000), the ligation state of integrin
 
 
 
v
 
 
 
5 and Src kinase activity in normal animals are critical
during VEGF-induced angiogenesis in vivo (Friedlander et
al., 1995; Eliceiri et al., 1999).
Recent work from several laboratories indicates that Src
and focal adhesion kinase (FAK) are activated by growth fac-
tor receptors and/or after integrin-mediated cell adhesion
(Parsons and Parsons, 1997; Schlaepfer and Hunter, 1998).
Src and FAK also associate with the cytoplasmic domain of
growth factor receptors (Ralston and Bishop, 1985; Gould
and Hunter, 1988; Kypta et al., 1990; Sieg et al., 2000), and
after integrin-mediated cell adhesion, FAK can recruit Src to
focal adhesions leading to Erk activation (Courtneidge et al.,
1993; Aplin et al., 1998; Schlaepfer and Hunter, 1998;
Wary et al., 1998). In addition to Src, several adapter and
signaling molecules can associate with FAK (Cobb et al.,
1994; Schlaepfer et al., 1994), including p130
 
Cas
 
 (Polte and
Hanks, 1995), paxillin (Turner and Miller, 1994), PI 3-kinase
Figure 1.  VEGF promotes FAK 
phosphorylation and translocation in 
endothelial cells. (A) Lysates of VEGF-
stimulated primary HUVECs (20 ng/ml; 
5 min), mouse brain and lung brain 
(2  g/animal, 5 min) were prepared as 
described in Materials and methods and 
subjected to immunoblotting with anti-
phosphotyrosine antibodies specific for 
aa 397, 407, 576, 577, 861, or 925 within 
FAK. The sensitivity and specificity of 
the phosphospecific antibodies were 
characterized in various tissues as 
described in the Materials and methods. 
These immunoblots are representative 
of three different experiments. (B) Trans-
location of endogenous FAK in VEGF-
stimulated HUVECs (20 ng/ml; 5–60 
min) to focal adhesions was determined 
by indirect immunofluorescence with an 
anti-FAK antibody in representative
micrographs, as described in Materials and 
methods. Bar, 5  m. (C) Representative 
FAK activity in lysates of VEGF-stimulated 
HUVECs (20 ng/ml; 5–60 min) was 
measured by immune complex in 
triplicate in vitro kinase assays as 
described in Materials and methods
(P   0.05). (D) Lysates of VEGF-stimulated 
HUVECs (20 ng/ml; 2–60 min) were 
subjected to immunoblotting with an 
anti-phosphotyrosine antibody specific 
for aa 397, 861, an anti-phospho Erk 
antibody, or an anti-FAK antibody. Each 
of these panels are representative of 
triplicate experiments. 
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(Chen and Guan, 1994), and Grb2 (Schlaepfer et al., 1994).
However, the coordination of inputs from growth factor re-
ceptors leading to the selective recruitment or activation of
specific integrins in vivo remains poorly understood. To in-
vestigate the mechanism by which the VEGF pathway coor-
dinates with integrin 
 
 
 
v
 
 
 
5 and Src kinase, an in vivo angio-
genesis model was used with a defined growth factor input,
(i.e., VEGF), and a known requirement for a specific inte-
grin, i.e., 
 
 
 
v
 
 
 
5. Although we have previously shown an Src-
requirement for VEGF-mediated vascular responses (Eliceiri
et al., 1999; Paul et al., 2001), experiments were designed to
determine whether Src and its substrate, FAK, could func-
tionally regulate 
 
 
 
v
 
 
 
5 during the VEGF-mediated response
in intact blood vessels.
Evidence is provided that VEGF and other growth factors
activate Src kinase, which induces the phosphorylation of ty-
rosine 861 (Y861) within the FAK COOH terminus, facili-
tating the association of FAK with integrin 
 
 
 
v
 
 
 
5 both in vivo
and in vitro. Src deficiency or blockade of Src activity inhibits
the formation of a VEGF-induced FAK/
 
 
 
v
 
 
 
5 complex. In
contrast, both 
 
 
 
1 and 
 
 
 
3 integrins were found to couple to
FAK in the absence of growth factor stimulation. The physio-
logical relevance of this pathway is underscored by the finding
that mice lacking the integrin 
 
 
 
5 subunit, or mice deficient in
Src, have reduced VEGF-induced VP, suggesting a critical
role for integrin 
 
 
 
v
 
 
 
5, together with Src kinase activity, in
regulating VEGF-induced vascular responses in vivo.
 
Results
 
VEGF promotes FAK phosphorylation and 
translocation in endothelial cells
 
Previous studies from our laboratory demonstrated that Src
kinase activity (Eliceiri et al., 1999) and integrin 
 
 
 
v
 
 
 
5 liga-
tion (Friedlander et al., 1995) contribute to VEGF-medi-
ated angiogenesis and/or VP. Based on these findings, we
considered the role of FAK in VEGF-mediated vascular re-
sponses, as integrins as well as Src kinase(s) influence FAK
phosphorylation and activation, leading to downstream sig-
naling (for review see Aplin et al., 1998). To gain a molecu-
lar understanding of this phenomenon, experiments were
designed to determine which Src phosphorylation sites
within FAK were phosphorylated after VEGF stimulation.
As an initial approach, lysates of VEGF-stimulated pri-
mary human endothelial cells (HUVECs) or VEGF-treated
mouse tissues were immunoblotted with a panel of phos-
photyrosine-specific antibodies. These antibodies were di-
rected to the tyrosine-phosphorylated state of amino acids
(aa) 397, 407, 576, 577, 861, or 925 within FAK, to detect
the known substrate sites for Src. The profile of VEGF-
induced tyrosine phosphorylation in cultured HUVECs was
compared with lysates of mouse lung and brain tissues ex-
posed to VEGF (5 min) (Fig. 1 A). VEGF-induced robust
tyrosine phosphorylation of aa 397 and 861 on FAK within
cultured endothelial cells as well as in intact mouse tissues
(Fig. 1 A). Other tyrosines within FAK were phosphorylated
to a minimal degree or below the detection limit.
FAK is found in focal contacts where it promotes down-
stream integrin-mediated signals (Parsons and Parsons,
1997; Schlaepfer and Hunter, 1998). To assess the role of
VEGF in the recruitment of FAK to focal contacts, we ex-
amined the localization of FAK in quiescent or VEGF stim-
ulated endothelial cells. Serum-starved HUVEC monolayers
were treated for various times with VEGF, which induced
the subcellular translocation of a fraction of the endogenous
pool of FAK from a diffuse cytoplasmic distribution to focal
adhesions within 5 min, consistent with previous observa-
tions (Takahashi et al., 1999). This subcellular translocation
response was transient, as there was a complete loss of FAK
in focal adhesions within 60 min (Fig. 1 B). The kinetics of
the subcellular translocation correlated with a transient in-
crease in FAK activity (3.5-fold increase within 5 min), fol-
lowed by a decrease in FAK activity by 60 min in lysates of
these cells (Fig. 1 C). Based on the prominent VEGF-
induced tyrosine phosphorylation of aa 861 in endothelial
cells (Fig. 1 A) (Abu-Ghazaleh et al., 2001), lysates of
VEGF-stimulated HUVECs were immunoblotted with
phosphotyrosine-specific anti-FAKY397, FAK Y861, phos-
phospecific anti–mitogen-activated protein (MAP) kinase
(Erk), or anti-FAK antibodies (Fig. 1 D). Tyrosine phos-
phorylation of aa 861 within FAK was increased within 2–5
min, and returned to baseline levels within 60 min. The
VEGF-induced Erk phosphorylation completely paralleled
the kinetics of FAK phosphorylation, FAK activity and its
subcellular translocation. These findings reveal that VEGF
promotes a rapid but transient redistribution of FAK to fo-
cal contacts which parallels its activation kinetics, and the
induction of downstream signaling to ERK.
 
VEGF induces FAK phosphorylation and formation of a 
FAK/
 
 
 
v
 
 
 
5 complex in cultured endothelial cells
 
Ligation of integrin 
 
 
 
v
 
 
 
5 has been shown to be essential for
VEGF-induced angiogenesis (Friedlander et al., 1995), al-
though the mechanisms underlying the recruitment of intra-
cellular signaling proteins to integrins in vivo remains poorly
understood. For example, an autonomously expressed form
of FAK lacking kinase activity, FAK-related non-kinase
(Schaller et al., 1993), suppresses VEGF-induced angiogene-
sis (unpublished data), suggesting that FAK may have an es-
sential role in VEGF-mediated vascular responses. Whereas
data in Fig. 1 demonstrates that VEGF stimulation leads to
the phosphorylation of FAK on aa 397 and 861 (Fig. 1 A)
and its localization in focal contacts (Fig. 1 B), the capacity
for phosphorylated FAK to coordinate with integrins in
blood vessels is unknown. Therefore, lysates of starved or
VEGF-stimulated HUVECs were subjected to immunopre-
cipitation with anti-integrin antibodies. These immunopre-
cipitates were then probed for the presence of FAK. VEGF
induced a FAK/
 
 
 
v
 
 
 
5 complex in endothelial cells (Fig. 2 A)
that was associated with increased FAK phosphorylation
(Fig. 1) and kinase activity (Fig. 1 C). Unlike that seen with
 
 
 
v
 
 
 
5, 
 
 
 
v
 
 
 
3 showed a constitutive association with FAK
that did not increase in response to VEGF (Fig. 2 A). Other
angiogenic growth factors such as bFGF do not appear to
promote FAK/
 
 
 
v
 
 
 
5 coupling (Fig. 2 A, bottom). The speci-
ficity of the FAK/
 
 
 
v
 
 
 
5 complex was supported by blotting
for other candidate focal adhesion proteins. For example,
these 
 
 
 
v
 
 
 
5 immunoprecipitates were probed for paxillin,
p130
 
Cas
 
, or PKC, which can bind FAK/integrin complexes
(Fig. 2 B). Immunoblotting with an anti-phosphotyrosine 
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antibody did not reveal a significant population of addi-
tional tyrosine-phosphorylated proteins other than a 125-
kD protein, most likely FAK, in the 
 
 
 
v
 
 
 
5 immunoprecipi-
tations. Although we did not detect other proteins associated
with FAK/
 
 
 
v
 
 
 
5 complexes, this may be due to the brief
VEGF stimulation (5 min) used in this experiment.
 
Src kinase regulates the formation of a FAK/
 
 
 
v
 
 
 
5 
complex after VEGF stimulation in cultured endothelial 
cells or on the chorioallantoic membrane
 
 
 
of 10 1-d-old 
chick embryos during angiogenesis
 
Blockade of Src kinase activity (Eliceiri et al., 1999) or liga-
tion of integrin 
 
 
 
v
 
 
 
5 disrupts VEGF-mediated signaling
and angiogenesis, yet it fails to influence bFGF-mediated
angiogenesis (Friedlander et al., 1995). However, inhibition
of 
 
 
 
v
 
 
 
5 has no effect on VEGF-stimulated Src kinase activ-
ity (unpublished data). These findings suggest that Src func-
tions upstream of integrin 
 
 
 
v
 
 
 
5. Therefore, we considered
whether Src might be required for assembly of the FAK/
 
 
 
v
 
 
 
5 complex in VEGF-stimulated endothelial cells or tis-
sues. To test this possibility, we employed pharmacological
or genetic approaches to suppress Src kinase activity in cul-
tured endothelial cells in vitro or intact blood vessels in vivo.
Pharmacological inhibition of Src kinase with PP1 (Hanke
et al., 1996) or retroviral delivery of kinase-deleted Src (aa
1–251, Src 251) suppressed VEGF-induced levels of the
FAK/
 
 
 
v
 
 
 
5 complex in HUVECs (Fig. 3 A). To determine
whether VEGF could induce a FAK/ v 5 complex in blood
Figure 2.  VEGF-induced assembly of FAK with integrin  v 5 in 
endothelial cells. (A) FAK association with integrin  v 5 or  v 3 in 
HUVECs with or without VEGF (20 ng/ml; 5 min) was measured by 
immunoprecipitation from whole cell lysates with anti- v 5 or 
anti- v 3 monoclonal antibodies, respectively. These immune 
complexes were immunoblotted and detected with an anti-FAK 
antibody. Immunoblotting with an anti-phospho Erk antibody 
reveals the activation of the MAP kinase pathway in these VEGF-
stimulated endothelial cells. The bottom panel shows the association 
of FAK with  v 5 after stimulation with basic fibroblast growth 
factor. (B) The capacity for cytosolic proteins other than FAK to 
associate with  v 5 was determined by immunoblotting  v 5 
immunoprecipitates from VEGF-stimulated HUVEC lysates with 
anti-p130
Cas, paxillin, phosphorylated pan PKC, or phosphotyrosine 
antibodies. No background bands in the molecular weight range of 
FAK were detected by FAK immunoblotting of mock immunopre-
cipitations performed with anti- v 5 in the absence of cell lysate 
(shown above) or with control antibodies (i.e., anti-VEGFR2) in the 
presence of lysate (unpublished data).
Figure 3.  Src kinase regulates VEGF-induced assembly of a 
FAK/ v 5 complex in cultured endothelial cells and in the chick 
embryo during angiogenesis. (A) The Src kinase family inhibitor, PP1 
(Hanke et al., 1996) was used to inhibit (10  M; 2 min pretreatment) 
VEGF-induced assembly of the FAK/ v 5 complex in HUVECs (20 
ng/ml; 5 min). Retroviral gene delivery of GFP or a dominant negative 
Src, kinase-deleted Src (Src 251) was used to suppress Src kinase 
activity in VEGF-stimulated HUVECs as described in Materials and 
methods. (B) Induction of a FAK/ v 5 complex in the CAM was 
measured by stimulation of 10-d-old CAMs with VEGF (1  g/ml; 5 
min) as previously described (Eliceiri et al., 1999). Retroviral gene
delivery of Src 251 or control GFP, was used to suppress Src kinase 
activity in angiogenic blood vessels as previously described (Eliceiri 
et al., 1999). Lysates of these CAMs were subjected to immunopre-
cipitation with an anti- v 5 antibody and the immunoprecipitates 
immunoblotted with an anti-FAK antibody. These immunoblots were 
representative of at least three separate experiments.Src-mediated FAK/ v 5 coupling in VEGF pathway | Eliceiri et al. 153
vessels in vivo, chick chorioallantoic membranes (CAMs)
were stimulated with VEGF and analyzed for the presence of
a FAK/ v 5 complex. Lysates from VEGF-stimulated con-
tained elevated levels of the FAK/ v 5 complex, compared
with unstimulated controls (Fig. 3 B, top). The formation of
the VEGF-induced FAK/ v 5 complex was disrupted by
exposing these CAMs to an avian-specific retrovirus (RCAS)
expressing Src 251 (Fig. 3 B, bottom), providing genetic evi-
dence for a Src requirement for the VEGF-induced assembly
of the FAK/ v 5 complex in vivo.
VEGF-induced FAK phosphorylation and formation of a 
FAK/ v 5 complex is suppressed in src
 /  mice
Although disruption of multiple SFKs with Src 251 blocks
VEGF-mediated angiogenesis, mice lacking a single SFK
showed a selective loss of VEGF-mediated VP, suggesting
that multiple Src kinases can contribute to VEGF-depen-
dent angiogenesis, yet selective SFKs are important for VP
(Eliceiri et al., 1999; Paul et al., 2001). To substantiate the
VEGF-mediated Src requirement for the FAK/ v 5 associ-
ation, mice lacking pp60
c-src were injected with VEGF, and
the injected tissues analyzed for FAK phosphorylation and
assembly of the FAK/ v 5 complex. Lysates were prepared
from src
 /  or control mouse tissues (dermis) stimulated
with VEGF or saline and subjected to immunoblotting with
phospho-specific antibodies directed to aa 397 or 861.
VEGF induced an increase in FAK 397 and 861 phosphory-
lation in control mice, whereas only a minimal level of FAK
phosphorylation was detected in src
 /  mice (Fig. 4 A), sug-
gesting that FAK is an important substrate for Src after
VEGF stimulation in vivo. Although VEGF treatment in-
creased the level of FAK associated with integrin  5 in src
 / 
control animals (threefold), the formation of this complex
was significantly suppressed in src
  
/  mice (Fig. 4 B) (1.1-
fold). These results provide genetic evidence in mice to cor-
roborate the finding that the VEGF-induced phosphoryla-
tion of FAK and the association of phosphorylated FAK
with  v 5 depend on VEGF-mediated Src kinase activity.
A role for the growth factor–induced tyrosine 
phosphorylation of the COOH-terminal FAK
aa 861 for assembly with integrin  5 in vivo
VEGF stimulation induces FAK/ v 5 complex formation in
vivo and in cultured endothelial cells (Figs. 2–4). Although
both tyrosines 397 and 861 within FAK are prominently
phosphorylated after VEGF stimulation, it remains unclear
whether these sites are involved in the formation of the FAK/
 v 5 complex by phosphorylation of either of these sites. In
addition, it is important to determine whether FAK/ v 5
complexes can form in other cell types in response to other
growth factors. To address these questions and to determine
the functional requirement for tyrosines 397 and 861 in the
assembly of the FAK/ v 5 complex, epitope-tagged (hemag-
glutinin [HA]) full-length FAK constructs were expressed at
similar levels in human epithelial cells (HEK-293) (Fig. 5 A).
HA-tagged wild-type FAK (HA-FAK), or mutants of aa 397
(HA-FAK Y397F) or 861 (HA-FAK Y861F) were examined
for their capacity to associate with endogenous  v 5 in these
cells. Like the endothelial cell response to VEGF, epithelial
cells such as HEK-293 formed a FAK/ v 5 complex in re-
sponse to EGF, which was blocked by the Src inhibitor, PP1
(unpublished data). Lysates of EGF-stimulated HEK-293 cells
expressing FAK constructs were subjected to immunoprecipi-
tation with anti- v 5, and the immunoprecipitates were blot-
ted with anti-HA to detect FAK. Wild-type FAK or the
Y397F FAK mutant were readily detected in a complex with
 v 5, however the Y861F FAK mutant failed to form a com-
plex with  v 5 (Fig. 5 B). Immunoblotting of whole cell ly-
sates with an anti-HA antibody revealed equivalent expression
levels of each of these tagged FAK constructs (Fig. 5 B). These
findings reveal that the tyrosine at position 861 is critical for
the formation of FAK/ v 5 complex, and that this complex
may form in other growth factor–stimulated cell types.
To confirm the role of tyrosine phosphorylation of aa 861
in the formation of FAK/ v 5 complexes in VEGF-treated
endothelial cells, HA-tagged wild-type FAK or aY861F mu-
Figure 4.  VEGF-induced FAK phosphorylation and formation of 
FAK/ v 5 complex is reduced in src
 /  mice. (A) Lysates of VEGF-
stimulated mouse lungs (2  g i.v./animal; 5 min) from src
 /  or 
control mice were subjected to immunoblotting with a generic anti-
phosphotyrosine antibody, or anti-phosphotyrosine antibodies 
specific for aa 397 or 861 within FAK, as described in Materials and 
methods. (B) The dermis of the ears of src
 /  or src
 /  mice were 
injected intradermally with VEGF (500 ng) or PBS, and after 5 min, 
whole tissue lysates were prepared for immunoprecipitation with an 
anti- 5 antibody, followed by immunoblotting for FAK, an anti-
phosphotyrosine antibody specific for tyrosine 861 within FAK. 
Parallel lysates were subjected to immunoblotting with anti-FAK or 
 5 antibodies as loading controls. Laser scanning densitometry of 
the FAK/ v 5 complex in the top row revealed a threefold increase 
in FAK/ v 5 complex after VEGF stimulation in src
 /  compared 
with only a 1.1-fold increase in src
 / mice. These immunoblots 
were representative of at least three separate experiments.154 The Journal of Cell Biology | Volume 157, Number 1, 2002
tant FAK were expressed in HUVECs. After VEGF stimula-
tion, theY861F FAK mutant failed to associate with  v 5,
whereas the WT FAK construct formed a complex with
 v 5 (Fig. 5 C), consistent with the VEGF-induced cou-
pling of  v 5 with endogenous FAK in these cells (Fig. 2
A). These results suggest that the VEGF-induced tyrosine
phosphorylation of aa 861 is important in the formation of
the FAK/ v 5 complex in the endothelium.
Phosphorylation of the COOH-terminal FAK tyrosine 
861 regulates assembly with integrin  5 in vitro
Previous findings have shown that the membrane proximal re-
gion of the   integrin cytoplasmic tail can bind FAK in vitro
(Schaller et al., 1995), a region that is conserved between  1,
 3, and  5 integrins. In support of this, we show that inte-
grins  v 3 and  1 (Fig. 5 D) have a constitutive baseline as-
sociation with FAK, whereas only integrin  v 5 supports in-
creased assembly of a FAK/integrin complex in response to
VEGF and other growth factors (Figs. 2 A, 3 B, and 5). Fur-
thermore, the co-immunoprecipitation analysis of HA-FAK/
 v 5 in cultured cells suggests that the tyrosine phosphoryla-
tion of a specific aa, Y861 in the FAK COOH terminus, is
important for the FAK/ v 5 complex (Fig. 5). Therefore, to
further characterize the mechanism of the Src-mediated FAK/
 v 5 interaction, in vitro binding studies were performed us-
ing NH2- or COOH-terminal domains of FAK and various
full-length or truncated fusion proteins of  5 and  3 cy-
toplasmic tails. NH2-terminal (FAK NT; aa 1–410) and
COOH-terminal (FAK CT; aa 852–-1052) fragments of
FAK were subjected to in vitro phosphorylation with active
Src and allowed to bind to fusion proteins derived from inte-
grin  5 or  3 cytoplasmic tails. Src failed to phosphorylate
FAK NT in vitro (unpublished data), and therefore was not
used in subsequent in vitro binding assays. However, Src in-
duced tyrosine phosphorylation of the FAK CT in vitro as de-
tected with phosphotyrosine antibodies to aa 861 and 925
(Fig. 6 C). Mock-treated or phosphorylated FAK CT protein
was incubated with the full-length cytoplasmic tails of inte-
grin  5 (glutathione S-transferase [GST]: aa 716–772) or  3
(GST: aa 716–762) (Fig. 6 A). Integrin-bound FAK was cap-
tured with glutathione-Sepharose and analyzed by immuno-
blotting with an anti-FAK antibody. As expected from our pre-
vious results (Fig. 2), FAK was constitutively associated with
the full-length  3 cytoplasmic tail. Unexpectedly, some level
of constitutive association was detected in complex with full-
length  5. However, this may be anticipated, as  1,  3, and
 5 integrin cytoplasmic tails share considerable sequence ho-
mology, particularly at the membrane-proximal domain, in-
cluding the sequence (KLL[V/I]TIHDR[R/K]EFAKF] (Fig.
6 A,  ). Therefore, to determine the contribution of the se-
quences unique to the cytoplasmic tails of the  3 and  5 sub-
units, fusion proteins were prepared lacking the common
membrane proximal sequence. Binding assays of mock-
treated or phosphorylated FAK CT with these truncated  3
or  5 cytoplasmic tails revealed that Src-phosphorylated FAK
CT bound selectively to the  5 tail compared with the  3 cy-
toplasmic tail, whereas nonphosphorylated FAK CT failed to
bind either  3 or  5 cytoplasmic tails. To determine whether
the phosphorylation of tyrosine 861 within the FAK CT by
Src was required for the interaction of FAK with  5, a point
mutant of the FAK CT (Y861F) was evaluated. Although the
Src-phosphorylated FAK CT bound integrin  5, the mutant
FAK CT (Y861) failed to bind integrin  5 (Fig. 6 C) even
though it was phosphorylated on aa 925 as detected by immu-
noblot analysis (Fig. 6 C). These in vitro binding data with in-
tegrin tails lacking the membrane proximal domain are con-
Figure 5.  A role for the growth factor–induced tyrosine 
phosphorylation of the COOH-terminal FAK aa 861 for assembly 
with integrin  5 in vivo. (A) Various epitope-tagged (HA) FAK 
constructs (HA wild-type, Y397F, or Y861F) were expressed in 
HEK-293 cells, as previously described (Sieg et al., 2000). (B) Lysates 
of EGF-stimulated cells (20 ng/ml; 5 min) expressing these various 
FAK constructs were subjected to immunoprecipitation with an anti-
 v 5 antibody and immunoblotted with an anti-HA antibody to 
detect FAK/ v 5 complexes. Expression levels of each HA-tagged 
construct was confirmed by HA immunoblotting. (C) Association of 
HA-WT FAK or HA-Y861 mutant FAK with integrin  v 5 in VEGF-
stimulated HUVECs. Parallel blotting of HUVEC lysates with anti-HA 
antibody reveals transient expression levels of HA-tagged FAK 
constructs. (D) Lysates of VEGF or mock-treated HUVECs were 
analyzed for the VEGF-induced association of FAK with  v 5, 
 v 3, or  1 integrins by immunoprecipitation with anti- v 5, 
 v 3, or  1 antibodies and immunoblotting with an anti-FAK 
antibody. These immunoblots were representative from at least 
three different experiments.Src-mediated FAK/ v 5 coupling in VEGF pathway | Eliceiri et al. 155
sistent with the data from intact cells in which VEGF-induced
an increase in FAK/ v 5 but not FAK/ v 3 complexes. Al-
though the molecular basis of the interactions of many pro-
teins which associate with integrin tails remains poorly under-
stood, our findings suggest that the membrane proximal
domain of integrin tails may contribute to the formation of a
baseline of the FAK/integrin complex in vivo and in vitro.
VEGF induced VP defect in integrin  5–deficient mice
Although the in vitro findings provide an important insight
into the molecular basis of Src-mediated FAK/ v 5 interac-
tions in the VEGF pathway, the functional requirement for
integrin   v 5 in a VEGF-mediated vascular response re-
mained unknown. Previous studies have demonstrated that
VEGF-mediated endothelial responses depend on Src kinase
activity (Eliceiri et al., 1999) and integrin  v 5, but not
 v 3 (Friedlander et al., 1995). In support of this, mice
lacking a single Src family member such as pp60
c-src fail to
undergo VEGF-induced VP, whereas general suppression of
Src with kinase-deleted Src blocks VEGF- but not bFGF-
mediated angiogenesis (Eliceiri et al., 1999). Therefore, we
reasoned that if Src and  v 5 were both downstream of
VEGF and on a common signaling pathway, one might pre-
dict that mice lacking  v 5 would have a phenotype similar
to that of src
 /  mice. Control mice or those lacking integrin
 5 or  3 were intradermally injected with VEGF and evalu-
ated for VEGF-mediated VP. The  5-deficient mice had a
significant decrease in VEGF-induced VP compared with
control littermates (Fig. 7 A) (P   0.05), which paralleled
the loss of VP observed in src
 /  mice (Eliceiri et al., 1999;
Paul et al., 2001). Importantly, mice lacking  3 (Hodivala-
Dilke et al., 1999) showed control levels of VP (Fig. 7 A),
which is consistent with our previous findings that VEGF-
dependent vascular responses depend primarily on  v 5
(Friedlander et al., 1995). To corroborate these findings,
control mice or mice lacking  5 were subjected to a stereo-
tactic brain injection of saline or VEGF into the brain which
is known to compromise the blood brain barrier (Fig. 7 B)
(Eliceiri et al., 1999). The decrease in Evan’s blue extravasa-
tion in cerebral blood vessels of  5
 /  mice after VEGF ad-
ministration suggests that there is a requirement for integrin
 5 in the VEGF-mediated breakdown of the blood–brain
barrier. Furthermore, the decrease in VEGF-induced VP in
these  5-deficient mice was concomitant with a decrease in
brain damage after cerebral ischemia (Fig. 7 C). Together,
these results demonstrate an important role for integrin
 v 5 in VEGF-mediated endothelial responses in vivo that
appears identical to that seen in mice lacking pp60
c-src.
Discussion
VEGF is unique among angiogenic growth factors, as it
functions as both a mitogen/chemoattractant and as well as
an inducer of VP in blood vessels (Senger et al., 1983; Fer-
rara and Davis-Smyth, 1997). Recent studies indicate that
VEGF promotes integrin-dependent cell biological responses
in vivo and in vitro (Friedlander et al., 1995; Soldi et al.,
1999; Borges et al., 2000; Byzova et al., 2000), suggesting
that the coordination of inputs from the extracellular matrix
and growth factors are physiologically important. Although
growth factors and integrin-mediated cell adhesion are
known to activate nonreceptor tyrosine kinases such as FAK
and Src, the mechanisms by which growth factor–induced
biological processes in primary cells and tissues are regulated
by integrins remains poorly understood. In this report, evi-
dence is provided for a novel molecular mechanism to ex-
plain how Src can regulate integrin and growth factor–depen-
dent signaling within blood vessels stimulated with VEGF, a
process which may be applicable to other cell types.
An important finding of this study is that VEGF via Src
induces the site-specific tyrosine phosphorylation of FAK on
Figure 6.  Phosphorylation of the COOH-terminal FAK tyrosine 
861 regulates assembly with integrin  5 in vitro. (A) Alignment of 
the cytoplasmic tails of   integrin subunit for integrins  1,  3, and 
 5. Full-length fusion proteins of  3 and  5 cytoplasmic tails 
(dashed line), truncated  3 and  5 cytoplasmic tails lacking the 
membrane-proximal domain (solid line) used in this study, and 
previously mapped conserved peptide region of  1 integrin 
(Schaller et al., 1995; circles). Boxed regions represent conserved 
domains. (B) Associations between Src-phosphorylated FAK COOH 
terminus (FAK CT*) or mock-phosphorylated FAK CT (FAK CT) with 
GST fusions of full length  3 or  5 integrin cytoplasmic tails, or 
truncated  3 or  5 integrin cytoplasmic tails (5 min) were identified 
by immunoblotting glutathione-Sepharose pulldowns with an anti-
FAK antibody, as described in Materials and methods. These blots 
were representative of at least three different experiments. (C) (up-
per) Phosphorylated FAK CT or a mutant of tyrosine 861 within the 
FAK CT (FAK CT Y861F) was incubated with the truncated  5 
integrin cytoplasmic tail. (lower) Src-mediated phosphorylation of 
the FAK CT was determined by immunoblotting with phosphotyrosine 
specific anti-FAK antibodies recognizing aa 861 or 925.156 The Journal of Cell Biology | Volume 157, Number 1, 2002
Y861, leading to the formation of a complex between FAK
and  v 5 in both cultured endothelial cells in vitro and
blood vessels in vivo, and in EGF-stimulated epithelial cells.
These findings are consistent with the emerging role of aa
861 in mediating cell migration in tumor (Slack et al., 2001)
and endothelial cells (Abu-Ghazaleh et al., 2001). In this
study we have shown that Src deficiency or blockade of Src
activity suppresses FAK phosphorylation at aa 861, and
thereby reduces VEGF-induced FAK/ v 5 complex forma-
tion. These findings indicate that VEGF-induced Src activ-
ity and the phosphorylation of Y861 in FAK contribute to
the formation of a FAK/ v 5 complex. Although baseline
levels of FAK associate with integrins  1,  3, and  5, only
the  5 integrin supports increased levels of FAK/integrin
complexes after VEGF stimulation. Our data suggests that
this interaction depends on a region within the COOH-ter-
minal half of the  5 cytoplasmic tail that contains an aa se-
quence distinct from that of  1 or  3. Direct genetic evi-
dence for a role for integrin  v 5 in the VEGF pathway is
demonstrated in mice lacking integrin  5, which, like src
 / 
mice, have a defective VEGF-mediated VP response. In con-
trast, mice lacking integrin  3 have a normal VEGF-induced
VP response. In combination with the biochemistry from
endothelial cell immunoprecipitations and the in vitro bind-
ing assays, the lack of VEGF-mediated VP from Src or  5
knockout mice suggests that the VEGF-induced formation
of the FAK/ v 5 complex may be an important mechanism
for coordinating growth factor–dependent integrin signaling
during VEGF-mediated VP.
Previous studies from our laboratory demonstrate that
SFKs (Eliceiri et al., 1999) and integrin  v 5 (Friedlander
et al., 1995) are required for VEGF-induced angiogenesis
Figure 7.  VEGF-induced VP defect in 
integrin  5–deficient mice. (A) The 
VEGF-induced VP response in the dermis 
of  5
 / ,  3
 / , or control mice was 
determined by intradermal injection of 
VEGF (400 ng) into mice that had been 
previously injected with EB, a fluorescent 
VP indicator. The extravasation of EB 
from the blood vessels was quantitated 
by fluorimetry (O.D.600), as previously 
described (Eliceiri et al., 1999). (n   7) 
(*, P   0.05) (B) The VEGF-induced VP 
response in cerebral blood vessels was 
identified by the extravasation of EB 
from  5
 /  or control mice that had 
been stereotactically injected with VEGF 
or saline, as previously described 
(Eliceiri et al., 1999; Paul et al., 2001). 
Laser confocal scanning microscopy was 
used to visualize the fluorescence of the 
extravasated EB in representative brain 
cross sections. Bar, 100  m. (C) Infarct 
volumes following cerebral ischemia 
were determined in TTC-stained coronal 
sections of  5
 /  or control mice, as 
previously described (Paul et al., 2001). 
Quantitation of the infarct volumes was 
measured as previously described (Paul et 
al., 2001) (P   0.02) (left). Representative 
micrographs of TTC-stained brain sections 
reveal the zone of VEGF-mediated 
neuronal damage (right). Bar, 2 mm.Src-mediated FAK/ v 5 coupling in VEGF pathway | Eliceiri et al. 157
and VP. In contrast, bFGF-induced angiogenesis depends
on the ligation of integrin  v 3 (Friedlander et al., 1995),
and is independent of Src kinase activity (Eliceiri et al.,
1999). Several other signaling molecules, such as PKC or
eNOS, selectively contribute to the VEGF pathway (Fried-
lander et al., 1995; Ziche et al., 1997), suggesting that at
least some of the upstream components of the VEGF and
bFGF signaling pathways are distinct.
In addition to the role of VEGF as a mitogen and a VP
factor, a functional role for VEGF in inducing edema and
tissue damage has been identified after cerebral ischemia
(van Bruggen et al., 1999). Direct genetic evidence for the
pathophysiological relevance of integrin  v 5 in the VEGF
pathway is provided by the observation of a reduction in
neuronal damage in  5-deficient mice after cerebral isch-
emia (Fig. 7 C). We have previously shown that Src defi-
ciency or blockade of Src activity prevents VEGF-mediated
VP, thereby reducing neuronal damage after stroke (Paul et
al., 2001). In combination with the reduction in VEGF-
induced VP (Fig. 7) and neuronal damage in  5
 /  mice,
these results suggest a link between integrin  v 5 and the
Src-dependent VEGF vascular response in vivo.
Evidence from several cell models indicates that integrin
 v 5 mediates cell biological processes that require costimu-
lation with growth factors. For example,  v 5-mediated cell
adhesion, migration/invasion requires prestimulation with
growth factors (Klemke et al., 1994; Brooks et al., 1997;
Doerr and Jones, 1996; Lewis et al., 1996). In contrast,
 v 3-mediated cell migration/invasion in these cells are in-
dependent of growth factor stimulation. These studies sug-
gest that in contrast to  v 3, integrin  v 5 may require an
upstream priming signal from an activated growth factor re-
ceptor leading to Src kinase activation for biological func-
tion of the integrin  v 5 and downstream signaling. The
capacity for HEK-293 epithelial cells to form an Src-depen-
dent FAK/ v 5 complex in response to EGF and our results
with VEGF-stimulated endothelial cells suggests that this
pathway may have a general significance for a wide range of
cell types in response to specific growth factors.
Data presented here indicate that a FAK/integrin complex
can form in an integrin-specific manner depending on the
stimulus. Although FAK can bind the membrane distal re-
gion of the  1 integrin tail (Lewis and Schwartz, 1995;
Klingbeil et al., 2001), the FAK NH2 terminus binds a con-
served membrane proximal  1 integrin cytoplasmic tail se-
quence (Schaller et al., 1995). The molecular basis of this
constitutive baseline association of FAK with the membrane
proximal region of   integrins remains unknown; however, it
is possible that the Src-mediated association of the FAK CT
with the truncated  5 cytoplasmic tail may depend on a  5-
specific distal sequence(s). There are no obvious motifs
within the integrin  5 cytoplasmic tail, such as a phosphoty-
rosine binding domain that might account for such an inter-
action, but evidence presented here suggests that Src-medi-
ated tyrosine phosphorylation of the FAK CT at aa 861 can
contribute to the FAK/ v 5 association. It is conceivable
that phosphorylation of aa 861 influences the structure of
FAK through intramolecular rearrangement, enabling it to
bind the cytoplasmic tail of integrin  5. This may involve
more than one interaction, such that the FAK NT might as-
sociate with the membrane proximal region of the   integrin
cytoplasmic tail, as suggested by previous workers (Schaller et
al., 1995), whereas the FAK CT associates selectively with
the COOH terminus of the  5 integrin cytoplasmic tail. Re-
cent findings indicate that the FAK NT may be important
for coordinating with growth factors receptors (Sieg et al.,
2000), whereas tyrosine phosphorylation of aa 861 in the
FAK CT is increased during integrin-mediated cell migration
(Abu-Ghazaleh et al., 2001; Slack et al., 2001). Furthermore,
our data with different FAK mutants suggest that wild-type
FAK interacts with  v 5 through mechanism(s) distinct
from Y397F/ v 5 interactions. Not surprisingly, the Y397F
mutation of aa 397 influences a wide range of other phos-
phorylation events, which may complicate the interpretation
of this mutant in these assays. Indeed, phosphorylation of
Y397 (Wennerberg et al., 2000), Y925 and other sites within
FAK may influence the complexity of integrin-associated
proteins in vivo, and mediate baseline levels of FAK/integrin
interactions. We believe that the design of the in vitro bind-
ing assays with the FAK COOH terminus lacking aa 397, fa-
cilitates the analysis of the potential role of aa 861 in mediat-
ing growth factor–dependent interactions with the distal
portion of the integrin tail. Although our in vitro binding
data suggests that the FAK/ v 5 complex forms in the ab-
sence of other proteins, it is possible that other focal-adhesion
associated proteins (for review see Aplin et al., 1998) can as-
sociate with this FAK/ v 5 complex in cells.
Evidence is provided that endothelial cells can coordinate
VEGF-induced vascular responses through a specific inte-
grin-mediated signaling mechanism. Although both Src ki-
nase and integrin  v 5 are necessary for these VEGF re-
sponses in blood vessels, we propose that the Src-mediated
association of FAK with  v 5 represents a novel mechanism
for the coordination of different integrin and growth factor–
dependent biological processes and may be applicable to var-
ious cell types in vivo.
Materials and methods
Antibodies and reagents
A rabbit polyclonal antibody raised against the COOH terminus of human
FAK (C-20; Santa Cruz Biotechnology) was used for immunoprecipitations
for in vitro kinase assays and immunoblotting. The anti-HA antibody was
from Covance Research Products. Monoclonal antibodies directed to  v 3
(LM609) or  v 5 (P1F6) used for integrin immunoprecipitations from human
or chick tissues. Rabbit polyclonal anti- 5 antibodies used to immunopre-
cipitate mouse integrin  v 5 were from either Dr. M. Hemler (Harvard Uni-
versity, Boston, MA) (Ramaswamy and Hemler, 1990) or Chemicon Interna-
tional. The phospho-specific MAP kinase antibody was from New England
Biolabs, and the phospho-FAK antibodies directed to tyrosines 397, 407,
576, 577, 861, or 925 were from Biosource. The specificity of these site-spe-
cific anti-phosphotyrosine antibodies targeting FAK was confirmed by im-
munoblotting various FAK mutants expressed in vitro, in cultured cells, and/
or based on previous findings with these reagents (Sieg et al., 2000). RCAS
(A)-GFP, and Src 251 were gifts of Dr. P. Schwartzberg (National Institutes of
Health, Bethesda, MD) and H. Varmus (Sloan-Kettering, New York, NY).
pLNCX–FAK-related non-kinase constructs were a gift of Dr. T. Parsons (Uni-
versity of Virginia, Charlottesville, VA). HUVECs were obtained from Bio-
whittaker. VEGF was from Peprotech, and bFGF was a gift of Dr. J. Abraham
(Scios, Mountain View, CA). Protein A/G was from Pierce Chemical Co., and
glutathione-Sepharose was from Amersham Pharmacia Biotech. All other re-
agents and media were from Sigma-Aldrich.
HUVEC, HEK-293, chick embryo, and mouse treatments
Low-passage (P2-P5) HUVEC were serum starved for 16 h in serum-free
media before stimulation with growth factors. Gene delivery of various158 The Journal of Cell Biology | Volume 157, Number 1, 2002
constructs into HUVECs was performed by retroviral infection using the
replication-defective murine Moloney retrovirus pLNCX and amphotropic
packaging cells ( NX-Ampho, a gift of G. Nolan, Stanford University,
Stanford, CA) as described previously (Eliceiri et al., 1999). HEK-293 cells
expressing various FAK constructs (HA-tagged full-length wildtype FAK, or
mutants Y397F and Y861F) were pooled populations of cells expressing
HA-tagged FAK proteins. Both HUVECs and 293 cells were serum starved
for 16 h in serum-free media before VEGF or EGF stimulation, respectively.
Fertilized chick embryos (McIntyre Farms) were stimulated with growth
factors or infected with retroviruses as previously described (Eliceiri et al.,
1999). High-titer avian-specific retroviruses used for the transduction of
CAM tissue with mutant constructs were prepared as previously described
(Eliceiri et al., 1999). 48 h after infection with the retroviruses expressing
GFP or mutant Src 251, chick CAMs were stimulated with VEGF for 5 min,
and lysates were prepared for analysis.
 5
 /  and control  5
 /  mice were generated as previously described
(Huang et al., 2000).  3
 /  mice were generated as previously described
(Hodivala-Dilke et al., 1999). Src
 /  and src
 /  mice were generated as
previously described (Soriano et al., 1991), and were a gift of Drs. P. Sori-
ano (Fred Hutchinson Cancer Research Center, Seattle, WA), P. Stein (Uni-
versity of Pennsylvania, Philadelphia, PA), and P. Schwartzberg. Systemic
intravenous VEGF injections (2  g/animal in 100  l), stereotactic brain in-
jections and intradermal ear injections of anesthetized mice was per-
formed with VEGF (500 ng in 5  l) as previously described (Eliceiri et al.,
1999). Statistical analysis of the quantitation of mouse matrigel angiogene-
sis, VP, and ischemia assays was performed with the Student t test.
Immunoprecipitation, immunoblotting, kinase assays, 
and immunostaining
For coimmunoprecipitation of FAK with integrin  v 5 in HUVECs, lysis
was performed in a buffer (HNG) containing 1% Brij (HNG buffer: 50 mM
Hepes, pH 7.4, 150 mM NaCl, 10% glycerol) (Berditchevski et al., 1997),
and the lysates diluted with one volume of PBS for immunoprecipitation.
For the HUVEC in vitro kinase assays and immunoprecipitation of FAK/
 v 5 complexes from mouse tissues, lysates were prepared in modified
RIPA buffer as described previously (Eliceiri et al., 1999) and diluted with
PBS for immunoprecipitation. To detect FAK/ v 5 complexes in CAM tis-
sue and HEK-293 cells, lysates were prepared in HNG buffer with 1.0%
TX100 using a motorized grinder as necessary. SDS-PAGE and immuno-
blotting were performed as previously described (Eliceiri et al., 1999). FAK
activity was measured by the ability of immunoprecipitated FAK to phos-
phorylate poly-Glu-Tyr (4:1) in an in vitro kinase assay. FAK was immuno-
precipitated from equivalent amounts of protein from whole cell lysates as
described above, subjected to the kinase assay, and the samples were ana-
lyzed by 16% SDS-PAGE as previously described (Eliceiri et al., 1998). Im-
munostaining of serum-starved HUVEC in the presence or absence of
VEGF was performed with an anti-FAK antibody (Abedi and Zachary,
1997) and fixed in acetone as previously described (Takahashi et al.,
1999).
In vitro binding assay
GST fusion proteins of NH2- and COOH-terminal fragments of FAK and
various  3 and  5 integrin cytoplasmic tails were prepared in Escherichia
coli (BL21[DE3]). The FAK constructs were phosphorylated in vitro with
active Src kinase (UBI), and the GST domain removed from the FAK con-
structs by Factor Xa (Amersham Pharmacia Biotech) cleavage. The integrin
tail constructs retained the GST domain to facilitate the pulldown of FAK/
integrin complexes after incubation with glutathione-Sepharose after 5–10
min in PBS on ice. Complexes were resolved by 16% SDS-PAGE and im-
munoblotted with anti-FAK or phosphospecific Y861 and Y925 antibodies.
In vivo VP models
Extravasation of Evan’s Blue (EB) in the dermis after intradermal injection
of VEGF was quantitated by extraction with formamide and spectropho-
tometry of eluted EB dye (Eliceiri et al., 1999). Laser scanning confocal mi-
croscopy was used to visualize the VP of cerebral blood vessels by detec-
tion of the fluorescence of the EB dye in brain cross sections (Eliceiri et al.,
1999; Paul et al., 2001). Cerebral ischemia experiments were performed as
previously described (Paul et al., 2001). In brief, permanent occlusion of
the middle cerebral artery was performed in anesthetized mice by coagu-
lation using a heating filament (Nawashiro et al., 1997). The brains were
removed after 24 h and the infarcts determined by staining 1-mm coronal
brain sections with 2% TTC. The infarct was measured from digital images
of the sections and the volume calculated by summing the infarcted non-
stained areas multiplied by their thickness (Eliasson et al., 1997). 
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